PriceTargets.com logo

Impel Pharmaceuticals - IMPL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/21/2023 12:59 AM ET
+0 (0.00%)
Get New Impel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMPL

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Impel Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for IMPL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Impel Pharmaceuticals. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/21/2022GuggenheimLower Target$14.00
11/17/2022CowenLower Target$40.00
11/15/2022WedbushDowngradeOutperform ➝ Neutral$24.00 ➝ $5.00
8/24/2022JonestradingInitiated CoverageBuy$26.00
9/3/2021CowenBoost TargetOutperform$35.00 ➝ $55.00
5/18/2021CowenInitiated CoverageOutperform$35.00
5/18/2021WedbushInitiated CoverageOutperform$21.00
5/18/2021GuggenheimInitiated CoverageBuy$32.00
(Data available from 1/17/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Impel Pharmaceuticals logo
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.27
Low: $0.04
High: $0.84

52 Week Range

Now: N/A

Volume

720,000 shs

Average Volume

682,655 shs

Market Capitalization

$956 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Impel Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Impel Pharmaceuticals in the last twelve months:
View the latest analyst ratings for IMPL.

What is the current price target for Impel Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Impel Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Impel Pharmaceuticals in the next year.
View the latest price targets for IMPL.

What is the current consensus analyst rating for Impel Pharmaceuticals?

Impel Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMPL.

What other companies compete with Impel Pharmaceuticals?

Other companies that are similar to Impel Pharmaceuticals include Enveric Biosciences, Tharimmune, NovaBay Pharmaceuticals, Artelo Biosciences and Lipella Pharmaceuticals. Learn More about companies similar to Impel Pharmaceuticals.

How do I contact Impel Pharmaceuticals' investor relations team?

The company's listed phone number is 206-568-1466. The official website for Impel Pharmaceuticals is www.Impelnp.com. Learn More about contacing Impel Pharmaceuticals investor relations.